Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
July 25, 2019: Challenges in viral suppression for young, black women; stigma's impact on women's health; generalized anxiety disorder screening needed; how depression harms the brain.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Having Fallen Out of Care, Most Gay and Bisexual Men With Detectable HIV Viral Loads Were Successfully Reconnected, Study Finds
The study enrolled more than a thousand people in four U.S. cities: Atlanta, Baltimore, Birmingham, and Boston.
The U.S. Food and Drug Administration has approved a three-drug regimen to treat complicated urinary tract infections and complicated intra-abdominal infections, both of which can be especially problematic for people living with HIV.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.